Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Neoplasms 6Multiple Myeloma 4Kidney Neoplasms 3Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Lymphoma 1Liver Neoplasms 1Leukemia 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × perifosine × Clear all
NCT00455559 2018-02-22

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

AEterna Zentaris

Phase 2 Completed
40 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡